Healio (4/5, Marabito) reports, “Cholinesterase inhibitors provided moderate but persistent benefits in patients with Alzheimer’s dementia, including a lower risk for death,” investigators concluded, but “galantamine was the only the cholinesterase inhibitor (ChEI) that demonstrated a significant reduction in the risk for severe dementia.” Investigators arrived at these conclusions after comparing 11,652 patients with Alzheimer’s “who were started on ChEIs within three months of their dementia diagnosis – either donepezil, rivastigmine or galantamine – and 5,836” patients with Alzheimer’s “who did not take ChEIs.” The findings were published online in the journal Neurology. (SOURCE: APA Headlines)